Side Effects of rolapitant: A Synthesis of Findings from 5 Studies

  1. Home
  2. Side Effects of rolapitant
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of rolapitant: A Synthesis of Findings from 5 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of rolapitant: A Synthesis of Findings from 5 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main findings

Rolapitant is a highly selective neurokinin-1 (NK-1) receptor antagonist that is effective in preventing chemotherapy-induced nausea and vomiting (CINV). 4

Two randomized, double-blind, phase 3 trials showed that rolapitant was effective in preventing CINV in patients receiving highly emetogenic chemotherapy, such as cisplatin-based regimens. 2

Another randomized, double-blind, phase 3 trial demonstrated that rolapitant is also effective in preventing CINV in patients receiving moderately emetogenic chemotherapy or regimens containing an anthracycline and cyclophosphamide. 3

Reasons for side effects

Rolapitant is an NK-1 receptor antagonist, which blocks the action of substance P, a neurotransmitter involved in the central nervous system signaling of nausea and vomiting. 4

Common side effects

Constipation

Constipation is one of the most common side effects of rolapitant. 2 3

Fatigue

Fatigue is another common side effect of rolapitant. 2 3

Nausea

Nausea can also be a side effect of rolapitant. 2 3

Rash

Rash is also a possible side effect of rolapitant. 2 3

Abdominal pain

Abdominal pain has been reported as a side effect of rolapitant. 2 3

Side effect management

Constipation

Constipation can be managed by increasing dietary fiber intake and drinking plenty of fluids. If constipation persists, consult your doctor. 2 3

Fatigue

Fatigue can be managed by getting enough rest and engaging in light exercise. If fatigue persists, consult your doctor. 2 3

Nausea

Nausea can be managed by eating small, frequent meals and choosing bland foods. If nausea persists, consult your doctor. 2 3

Rash

If you develop a rash, consult your doctor. 2 3

Abdominal pain

If you experience abdominal pain, consult your doctor. 2 3

Comparison of studies

Commonalities

All these studies show that rolapitant is effective in preventing CINV. 2 3

Differences

These studies differ in the dosage of rolapitant used. 2 3

Real-life application considerations

Rolapitant is an effective medication for preventing CINV, but it is important to be aware of the potential side effects. If you are considering using rolapitant, discuss the potential risks and benefits with your doctor. 2 3

Limitations of current research

Further research is needed to evaluate the long-term safety and efficacy of rolapitant. 2 3

Future research directions

Further research is needed to evaluate the long-term safety and efficacy of rolapitant. 2 3

Conclusion

Rolapitant is an effective medication for preventing CINV, but it can have side effects. Discuss the risks and benefits with your doctor before using rolapitant. 2 3

Literature analysis of 5 papers
Positive Content
4
Neutral Content
1
Negative Content
0
Article Type
2
1
0
1
5
1.

Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.

Author: YanJun-Hong, GuWan-Jie, PanLei

Exacerbation reduction
FEV1 improvement
Diarrhea
Headache
Insomnia
Nausea
Weight loss

Roflumilast significantly reduces the mean exacerbation rate in COPD patients. Although there are insufficient clinical evidence on other clinical endpoints and high risk of some adverse events, roflumilast therapy may benefit COPD patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

2.

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.

Author: RapoportBernardo L, ChasenMartin R, GridelliCesare, UrbanLaszlo, ModianoManuel R, SchnadigIan D, PomaAllen, AroraSujata, KansraVikram, SchwartzbergLee S, NavariRudolph M

Nausea and vomiting prevention
Not specified

Rolanitant, an NK-1 receptor antagonist, is being investigated for its effectiveness in preventing chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.

Author: SchwartzbergLee S, ModianoManuel R, RapoportBernardo L, ChasenMartin R, GridelliCesare, UrbanLaszlo, PomaAllen, AroraSujata, NavariRudolph M, SchnadigIan D

Nausea and vomiting prevention
Not specified

This study assessed the efficacy of rolapitant in combination with a serotonin (5-HT3) receptor antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.

Author: RapoportBernardo L

Chemotherapy side effects
Nausea
Vomiting

Rolapitant is a highly selective neurokinin-1 (NK-1) receptor antagonist with a long half-life and good oral activity, effectively controlling chemotherapy-induced nausea and vomiting (CINV). This review explores the unique pharmacological characteristics and clinical applications of rolapitant.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.